ProKidney (PROK) Expected to Announce Quarterly Earnings on Friday

ProKidney (NASDAQ:PROK) is anticipated to issue its Q1 2025 quarterly earnings data before the market opens on Friday, May 9th. Analysts expect ProKidney to post earnings of ($0.16) per share for the quarter.

ProKidney (NASDAQ:PROK) last announced its earnings results on Monday, March 17th. The company reported ($0.17) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.03). The company had revenue of $0.08 million during the quarter. On average, analysts expect ProKidney to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

ProKidney Stock Down 3.6 %

Shares of ProKidney stock opened at $0.85 on Friday. The company has a market cap of $249.96 million, a PE ratio of -1.55 and a beta of 1.52. The business has a 50 day moving average of $0.90 and a 200 day moving average of $1.46. ProKidney has a 52 week low of $0.46 and a 52 week high of $4.44.

Insider Activity at ProKidney

In other news, insider Control Empresarial De Capital purchased 1,032,218 shares of ProKidney stock in a transaction that occurred on Thursday, April 10th. The shares were bought at an average cost of $0.61 per share, with a total value of $629,652.98. Following the completion of the purchase, the insider now directly owns 72,592,325 shares in the company, valued at approximately $44,281,318.25. This trade represents a 1.44 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders acquired a total of 1,787,716 shares of company stock worth $1,175,419 over the last quarter. 41.49% of the stock is owned by corporate insiders.

About ProKidney

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease.